Pharmalot… Pharmalittle… The Weekend Nears
2 CommentsBy Ed Silverman // September 24th, 2010 // 6:53 am
And so the end of another work week is near. Which means the time has come to plan your weekend activities. Anything special in the offing? How about picking apples? Or a walk in the park? We plan to watch one of the short people on the football field and catch up on some reading. Meanwhile, another day awaits. So here are a few items to help you along. And whatever you do this weekend, have a great time…
Amgen And J&J Recall Some Anemia Meds (Reuters)
EMA Rejects Merck KGaA’s MS Pill (Bloomberg News)
Alnylam To Cut Up To 30 Percent Of Workforce (Associated Press)
Sanofi-Aventis Signs Deal With Dana Farber Cancer Institute (PharmaTimes)
Glaxo’s Advair Follow-Up Shows Promise In Tests (Reuters)
Xanodyne Pharma Plans Staff Cuts (The Cincinnati Enquirer)
EU Finds No Link Between Glaxo’s Pandremix And Narcolepsy (Reuters)
Novartis Hid Zometa Risks, Lawyer Tells Jury (Bloomberg News)
pix thx to carrera911e on flickr creative commons
Steve Knows
Ed,
You, of all people, need that nice weekend respite. Your hard work putting out this very informative information, sparing us a lot of extra work looking for that valuable information, is a BIG PLUS and time saver.
Meanwhile, follow your own advice, take it easy over the weekend.
Your bud,
Steve
industry insider
Timing is everything. Xanodyne started up nine years ago just as the “specialty pharmaceuticals” business model was beginning its slow, painful decline. The reality is that you can’t sell a line extension, reformulation, me-too, or simply a repackaging of an old product these days, call it “new”, and command a premium price. Dead, gone, and buried.